Peroxisomal β-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer
C. Y. Mah, A. D. T. Nguyen, T. Niijima, M. Helm, J. Dehairs, F. J. Ryan, N. Ryan, I. G. Mills, J. V. Swinnen, D. J. Lynn, Z. D. Nassar, L. M. Butler
This study identifies DECR2 as a key driver of treatment resistance in advanced prostate cancer by regulating lipid metabolism and cell cycle progression.
bioRxiv · Nov 5, 2022Cancer Biology